{"name":"EuroFarma","slug":"eurofarma","ticker":"Private","exchange":"Private","domain":"eurofarma.com.br","description":"EuroFarma is a private pharmaceutical company specializing in generics, biosimilars, and branded pharmaceuticals. The company focuses on developing and commercializing treatments for various therapeutic areas, including oncology and autoimmune diseases. EuroFarma's key products include its branded pharmaceuticals and biosimilars, which have gained significant market share in recent years. As a private company, EuroFarma's financial information is not publicly disclosed, but it is considered a major player in the generics and biosimilars market.","hq":"São Paulo, Brazil","founded":0,"employees":"","ceo":"Maurizio Billi","sector":"Generics / Biosimilars / Branded Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":2100000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1963-01-01","label":"Derma-Smoothe/Fs first approved","drug":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Fluocinolone Acetonide first approved","drug":"Fluocinolone Acetonide","drugSlug":"fluocinolone","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-08-12","label":"Derma-Smoothe/Fs patent expiry (Formulation)","drug":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-12","label":"Derma-Smoothe/Fs patent expiry (Formulation)","drug":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","type":"patent_expiry","sentiment":"negative"},{"date":"2028-11-07","label":"Derma-Smoothe/Fs patent expiry (Formulation)","drug":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Lupron patent cliff ($1.2B at risk)","drug":"Lupron","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Avastin patent cliff ($2.5B at risk)","drug":"Avastin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"neuroscience","drugs":[{"name":"N1087","genericName":"N1087","slug":"n1087","indication":"Other","status":"phase_3"},{"name":"Alenia","genericName":"Alenia","slug":"alenia","indication":"Other","status":"phase_3"},{"name":"Cymbalta®","genericName":"Cymbalta®","slug":"cymbalta","indication":"Other","status":"marketed"},{"name":"Dextralgen","genericName":"Dextralgen","slug":"dextralgen","indication":"Other","status":"phase_3"},{"name":"Heptar","genericName":"Heptar","slug":"heptar","indication":"Other","status":"phase_3"},{"name":"Lactase Oral Tablets","genericName":"Lactase Oral Tablets","slug":"lactase-oral-tablets","indication":"Lactose intolerance management","status":"phase_3"},{"name":"Liquaemin","genericName":"Liquaemin","slug":"liquaemin","indication":"Other","status":"phase_3"},{"name":"Placebo of the experimental drug","genericName":"Placebo of the experimental drug","slug":"placebo-of-the-experimental-drug","indication":"Other","status":"phase_3"},{"name":"Tylex","genericName":"Tylex","slug":"tylex","indication":"Other","status":"phase_3"},{"name":"Vesomni®","genericName":"Vesomni®","slug":"vesomni","indication":"Benign prostatic hyperplasia with lower urinary tract symptoms (obstructive and storage symptoms)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Comparator - Trimbow®","genericName":"Comparator - Trimbow®","slug":"comparator-trimbow","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Budecort Aqua","genericName":"Budecort Aqua","slug":"budecort-aqua","indication":"Allergic rhinitis","status":"phase_3"},{"name":"Foraseq®","genericName":"Foraseq®","slug":"foraseq","indication":"Maintenance treatment of asthma","status":"phase_3"},{"name":"Formoterol/Fluticasone","genericName":"Formoterol/Fluticasone","slug":"formoterol-fluticasone","indication":"Asthma maintenance and reliever therapy","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"N0877","genericName":"N0877","slug":"n0877","indication":"Type 2 diabetes","status":"phase_3"},{"name":"N0728","genericName":"N0728","slug":"n0728","indication":"Type 2 diabetes","status":"phase_3"},{"name":"N0783","genericName":"N0783","slug":"n0783","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Placebo Evogliptin","genericName":"Placebo Evogliptin","slug":"placebo-evogliptin","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Fluocinolone Acetonide","genericName":"FLUOCINOLONE","slug":"fluocinolone","indication":"Corticosteroid-responsive dermatoses","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Cosamin DS® (Nutramax)","genericName":"Cosamin DS® (Nutramax)","slug":"cosamin-ds-nutramax","indication":"Osteoarthritis pain and joint function support","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Derma-Smoothe/Fs","genericName":"FLUOCINOLONE ACETONIDE","slug":"fluocinolone-acetonide","indication":"Atopic dermatitis","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Filgrastim (Eurofarma)","genericName":"Filgrastim (Eurofarma)","slug":"filgrastim-eurofarma","indication":"Chemotherapy-induced neutropenia","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Higroton® Laboratório Novartis","genericName":"Higroton® Laboratório Novartis","slug":"higroton-laborat-rio-novartis","indication":"Hypertension","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Minoxidil Topical Foam","genericName":"Minoxidil Topical Foam","slug":"minoxidil-topical-foam","indication":"Androgenetic alopecia (male pattern baldness)","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"Nexium®","genericName":"Nexium®","slug":"nexium","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"pain","drugs":[{"name":"Noex","genericName":"Noex","slug":"noex","indication":"Major depressive disorder","status":"phase_3"}]}],"pipeline":[{"name":"Comparator - Trimbow®","genericName":"Comparator - Trimbow®","slug":"comparator-trimbow","phase":"phase_3","mechanism":"Trimbow is a triple-combination inhaler that combines a long-acting beta-2 agonist, an inhaled corticosteroid, and a long-acting muscarinic antagonist to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Fluocinolone Acetonide","genericName":"FLUOCINOLONE","slug":"fluocinolone","phase":"marketed","mechanism":"Small molecule","indications":["Corticosteroid-responsive dermatoses"],"catalyst":""},{"name":"N0877","genericName":"N0877","slug":"n0877","phase":"phase_3","mechanism":"N0877 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"N1087","genericName":"N1087","slug":"n1087","phase":"phase_3","mechanism":"The mechanism of action for N1087 is currently unknown.","indications":[],"catalyst":""},{"name":"Alenia","genericName":"Alenia","slug":"alenia","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Budecort Aqua","genericName":"Budecort Aqua","slug":"budecort-aqua","phase":"phase_3","mechanism":"Budecort Aqua is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.","indications":["Allergic rhinitis","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Cosamin DS® (Nutramax)","genericName":"Cosamin DS® (Nutramax)","slug":"cosamin-ds-nutramax","phase":"phase_3","mechanism":"Cosamin DS is a dietary supplement containing glucosamine and chondroitin that may help maintain cartilage structure and reduce joint inflammation in osteoarthritis.","indications":["Osteoarthritis pain and joint function support"],"catalyst":""},{"name":"Cymbalta®","genericName":"Cymbalta®","slug":"cymbalta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Derma-Smoothe/Fs","genericName":"FLUOCINOLONE ACETONIDE","slug":"fluocinolone-acetonide","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Atopic dermatitis","Chloasma","Choroiditis","Contact dermatitis","Discoid lupus erythematosus"],"catalyst":""},{"name":"Dextralgen","genericName":"Dextralgen","slug":"dextralgen","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Filgrastim (Eurofarma)","genericName":"Filgrastim (Eurofarma)","slug":"filgrastim-eurofarma","phase":"phase_3","mechanism":"Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow.","indications":["Chemotherapy-induced neutropenia","Severe chronic neutropenia","Mobilization of peripheral blood progenitor cells for autologous transplantation"],"catalyst":""},{"name":"Foraseq®","genericName":"Foraseq®","slug":"foraseq","phase":"phase_3","mechanism":"Foraseq is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease)"],"catalyst":""},{"name":"Formoterol/Fluticasone","genericName":"Formoterol/Fluticasone","slug":"formoterol-fluticasone","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, while fluticasone is a corticosteroid that reduces airway inflammation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Heptar","genericName":"Heptar","slug":"heptar","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Higroton® Laboratório Novartis","genericName":"Higroton® Laboratório Novartis","slug":"higroton-laborat-rio-novartis","phase":"phase_3","mechanism":"Higroton (chlorthalidone) is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion and reducing blood volume and blood pressure.","indications":["Hypertension","Edema associated with congestive heart failure or renal disease"],"catalyst":""},{"name":"Lactase Oral Tablets","genericName":"Lactase Oral Tablets","slug":"lactase-oral-tablets","phase":"phase_3","mechanism":"Lactase is an enzyme that breaks down lactose (milk sugar) into glucose and galactose for absorption in the small intestine.","indications":["Lactose intolerance management"],"catalyst":""},{"name":"Liquaemin","genericName":"Liquaemin","slug":"liquaemin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Minoxidil Topical Foam","genericName":"Minoxidil Topical Foam","slug":"minoxidil-topical-foam","phase":"phase_3","mechanism":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.","indications":["Androgenetic alopecia (male pattern baldness)","Hair loss in women"],"catalyst":""},{"name":"N0728","genericName":"N0728","slug":"n0728","phase":"phase_3","mechanism":"N0728 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"N0783","genericName":"N0783","slug":"n0783","phase":"phase_3","mechanism":"N0783 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Nexium®","genericName":"Nexium®","slug":"nexium","phase":"marketed","mechanism":"Nexium inhibits gastric acid secretion by blocking proton pumps in the stomach lining.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Prevention of NSAID-induced ulcers"],"catalyst":""},{"name":"Noex","genericName":"Noex","slug":"noex","phase":"phase_3","mechanism":"Noex is a medication that works by inhibiting the enzyme responsible for the breakdown of a certain neurotransmitter.","indications":["Major depressive disorder","Obsessive-compulsive disorder"],"catalyst":""},{"name":"Placebo Evogliptin","genericName":"Placebo Evogliptin","slug":"placebo-evogliptin","phase":"phase_3","mechanism":"Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Placebo of the experimental drug","genericName":"Placebo of the experimental drug","slug":"placebo-of-the-experimental-drug","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":[],"catalyst":""},{"name":"Tylex","genericName":"Tylex","slug":"tylex","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vesomni®","genericName":"Vesomni®","slug":"vesomni","phase":"phase_3","mechanism":"Vesomni is a combination of silodosin (alpha-1A adrenergic antagonist) and mirabegron (beta-3 adrenergic agonist) that addresses both obstructive and storage symptoms of benign prostatic hyperplasia.","indications":["Benign prostatic hyperplasia with lower urinary tract symptoms (obstructive and storage symptoms)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"EuroFarma Receives FDA Approval for Biosimilar","summary":"EuroFarma announced that it has received FDA approval for its biosimilar, which is a treatment for a common autoimmune disease.","drugName":"Biosimilar","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"EuroFarma Partners with CMO for Manufacturing Services","summary":"EuroFarma announced a partnership with a contract manufacturing organization (CMO) to provide manufacturing services for its products.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE0xTV83TmlVUjRLQllOZE45SUxlYy05dFc0X3RmMU9JSXRxNFRGaHdwNWEwODhBUVRqQkhIVGZ0UlkzY2ViWjNRYmJlN1pVVkROODYtTXhGVU5TUkRWcUxaMHhNaFlyQ2Fpenl0OEVCM0Y?oc=5","date":"2025-02-26","type":"pipeline","source":"Built In","summary":"10 Pharmaceutical Companies in Brazil to Know - Built In","headline":"10 Pharmaceutical Companies in Brazil to Know","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-09","type":"deal","source":"Valor International","summary":"Pharmaceutical companies seek partners to fund expansion - Valor International","headline":"Pharmaceutical companies seek partners to fund expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQZzlVNXZyRUk4QlNYX29SLTdld2ZpRktTWDFBRG8yS1hRUmdCWk1vQmpES09tdU0zajFzRjEwXzVYb3N6M1Z3dHFaMkR5RWZQQzRUZXktaldMcFJaTnhzbUhJa01HdWdJa2VwQmRYVlQ3TUl2OWRfa2NlZUl3bThUR2U2UkFQbjNkRWxBQmZsQlZjUUE?oc=5","date":"2023-09-28","type":"pipeline","source":"International Finance Corporation (IFC)","summary":"Tips on Growing a Pharma Business in Emerging Markets - International Finance Corporation (IFC)","headline":"Tips on Growing a Pharma Business in Emerging Markets - International Finance Corporation (IFC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1fVXY3SWFLYncxMjJHbkJNVEt1ZnV4dmtlbnBkd2VFdGQzUEZ6endMZVEwaEw2aXFmWVBac05XaENJODNrX1BUX3hra0o2cFhzcVBlMUdKeTZFSkc5YmZn?oc=5","date":"2023-07-30","type":"pipeline","source":"International Finance Corporation (IFC)","summary":"An interview with Marco Billi on what it takes to succeed in pharma - International Finance Corporation (IFC)","headline":"An interview with Marco Billi on what it takes to succeed in pharma - International Finance Corporation (IFC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNLVZNMTZHVlN5bG1hQ0JTSmh1MXlUMndGVDl5TDhmVWpmUV9fdmdVV1NoYXplMjlwT0pBbnhlekNYQUtCbE9fWEc3LXdvVkRLc3JBUGluNTNYZVRwdl91RmNrWVpRR0FYbGV1RXdDWDhkNDBsR3ZadTQwWENxcGpFakZ1cUlIZE1BMzU5ZTNoSWpyRkxjenF3VzE1M2ZWUE9CUXVSV0J0RDBfVDNsbExHRjhudUpuLU1EX3ZXQVp6bDRTSzByS0d1S3hHbHZlemdfMEhER3pYTl8tTk1FUjN1S09ncWM?oc=5","date":"2022-07-14","type":"pipeline","source":"PR Newswire","summary":"SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America - PR Newswire","headline":"SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQU2h5dWJCdE04QTk3NXRiSXhpLTRJbkRIZXgzVHQ5dkVWLUhHZmctNFBxblpzXzhqenY5QXI0dEJEcy1qamlTTXpiTjlMMDhKUTJoYXVqaGVpZG5HUVowcTE5ZG5aWlBwX3dBZ0J6OWRkSi1rQXFwMzk3TkFBV1NGM1lsTkhwdw?oc=5","date":"2021-07-03","type":"patent","source":"Generics and Biosimilars Initiative","summary":"The pharmaceutical market in Brazil - Generics and Biosimilars Initiative","headline":"The pharmaceutical market in Brazil","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaEE1Y0p2SjZqc05lS2tyeVBPRVFFRFZtNVIxdmd5MGdwV0s0OEgzT1JLOU9fTkZrbjJYdzUyaWFUZWh2ZkFLSkROcEZIV1poMHM0NUhUckpVN0J4eWYxY1EycmlLdFVpc09GSXdqWk90VEJ0a3lSRFZPbFl6ZVpENTVsX3ZZX2FZWHBLbE5nRkNCQ3BaUnduS3pKWS1iek9ZQXB6NUVvT0xFcWdmc19IUQ?oc=5","date":"2019-04-05","type":"deal","source":"Fierce Pharma","summary":"Takeda scouts buyers for Latin America business, a deal that could fetch $1B: report - Fierce Pharma","headline":"Takeda scouts buyers for Latin America business, a deal that could fetch $1B: report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxPeC1yS3JUdHdZSmgyM2lFM2ZhaTNseHhlQjhHNkFCcmQ1SklfYUZ0VGtlQVBzNlR5T2NnbXJJSjY4M0ROOXlTTUFlWG1SNl8yVmVEZFk2aEtLRTZ6RlJFZE1zQjI0U210cFVGdWNsNGxEZW1lZ05DNFM0MzhvckRNZlgyM2d1Z1BWcWZYbkhTbmp6cXFpb3ZRRFdqNl9oV3pMYS1HLWQtelAxQ2tIV3gtTzJGZnVDdHFFQS15R2pjQnFGYXFCZUl1SFYwU3FIRjVzS0xQM1FjMmJza0tqQ0tsSUN1SjVsN3E4NU5USklJbk14d2JSMDBVbE9Yd1ZGZ2tMcHFLTzB2cWVYSDlLeGNQN21QbmFtMWZNemtGRlhmZzJKQQ?oc=5","date":"2012-02-15","type":"patent","source":"Via Ritzau","summary":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Via Ritzau","headline":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generi","sentiment":"neutral"}],"patents":[{"drugName":"Lupron","drugSlug":"leuprolide","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Avastin","drugSlug":"bevacizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","patentNumber":"8871241","type":"Formulation","expiryDate":"2027-08-12","territory":"US","genericFilings":[]},{"drugName":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","patentNumber":"7998108","type":"Formulation","expiryDate":"2028-01-12","territory":"US","genericFilings":[]},{"drugName":"Derma-Smoothe/Fs","drugSlug":"fluocinolone-acetonide","patentNumber":"9849027","type":"Formulation","expiryDate":"2028-11-07","territory":"US","genericFilings":[]}],"drugCount":26,"phaseCounts":{"phase_3":22,"marketed":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sandoz","Mylan","Teva"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":null,"yahoo":null}